Rezolute Inc Aktie News

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options

SAN FRANCISCO , Dec. 18, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI").

Rezolute stock fell over 85% on December 11. Block & Leviton is investigating Rezolute for possible securities fraud. Investors should contact the firm.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310).  [You ...

SAN FRANCISCO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (“erso”). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism (“HI”).

SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI").

RZLT Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Dec. 12, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment fo...

SAN FRANCISCO--(BUSINESS WIRE)--On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (“erso”). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism (“HI”). The news, analyst moves...